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Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide. The lack of tumor specificity remains a major
drawback for effective chemotherapies and results in dose-limiting toxicities. However, a ligand-mediated drug delivery
system should be able to render chemotherapy more specific to tumor cells and less toxic to normal tissues. In this study,
we isolated a novel peptide ligand from a phage-displayed peptide library that bound to non-small cell lung cancer (NSCLC)
cell lines. The targeting phage bound to several NSCLC cell lines but not to normal cells. Both the targeting phage and the
synthetic peptide recognized the surgical specimens of NSCLC with a positive rate of 75% (27 of 36 specimens). In severe
combined immunodeficiency (SCID) mice bearing NSCLC xenografts, the targeting phage specifically bound to tumor
masses. The tumor homing ability of the targeting phage was inhibited by the cognate synthetic peptide, but not by a
control or a WTY-mutated peptide. When the targeting peptide was coupled to liposomes carrying doxorubicin or
vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer
xenografts markedly increased. Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-
fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable
doxorubicin. The current study suggests that this tumor-specific peptide may be used to create chemotherapies specifically
targeting tumor cells in the treatment of NSCLC and to design targeted gene transfer vectors or it may be used one in the
diagnosis of this malignancy.
Citation: Chang D-K, Lin C-T, Wu C-H, Wu H-C (2009) A Novel Peptide Enhances Therapeutic Efficacy of Liposomal Anti-Cancer Drugs in Mice Models of Human
Lung Cancer. PLoS ONE 4(1): e4171. doi:10.1371/journal.pone.0004171
Editor: Nils Cordes, Dresden University of Technology, Germany
Received July 9, 2008; Accepted December 2, 2008; Published January 12, 2009
Copyright:  2009 Chang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Research Grants from Academia Sinica (#5202402020-0 to HCW) and National Science Council (NSC-96-2323-B-002-015
and NSC96-3114-P-001-006-Y02 to HCW).
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hcw0928@gate.sinica.edu.tw
Introduction
Lung cancer is one of the most commonly diagnosed
malignancies in developed countries and is a growing problem
in developing countries [1]. There are two major types of lung
cancer: non-small cell lung cancer (NSCLC) and small cell lung
cancer (SCLC). NSCLC makes up approximately 80% of all lung
cancer cases [2] and has a limited response rate to current
chemotherapeutic agents, with tumor shrinkage in only 20% of
patients and a two-year survival rate between 10% and 16% [3].
One major reason for this unsatisfactory outcome of chemother-
apy is compromised drug delivery to the lung cancer tissues due to
high interstitial fluid pressures (IFP) within the tumor [4].
Systemically administered chemotherapy cannot be adequately
delivered into solid tumors because of the immature vasculature
with abnormal architecture [5] and leaky, heterogeneous vessel
walls [6] as well as the high IFP within tumor tissues [7,8].
Furthermore, a lack of tumor specificity allows anti-cancer drugs
to distribute indiscriminately to normal organs and tissues. Thus,
cancer cells are exposed to a lower concentration of the drug than
normal cells [9], resulting in not only decreased effectiveness but
also increased toxicity. Therefore, it is important to develop a
strategy to enhance the amount of drugs delivered to tumor tissues
in a targeted way while sparing normal tissues.
Efforts are ongoing to improve the therapeutic index of
anticancer agents, either by increasing the drug concentration
inside the tumor or by decreasing it in normal host tissues [10].
Compared with conventionally administered chemotherapeutic
agents, lipid- or polymer-based nano-medicine drug delivery
systems have the advantage of improving the pharmacological and
therapeutic properties of cytotoxic drugs [11]. Most small-
molecule chemotherapeutic agents have a large volume of
distribution on intravenous administration [12] and a narrow
therapeutic window due to serious toxicity to normal tissues. By
encapsulating drugs in nano-particles such as liposomes, scientists
can significantly reduce the volume of distribution and increase the
concentration of active drug within the tumor [13]. PEGylated
liposomal doxorubicin (with brand names of Doxil in the US and
Caelyx in Europe) [14] has been shown to significantly improve
the therapeutic index of doxorubicin both in preclinical [15–17]
and clinical studies [18–21]. Several drug delivery systems of this
kind have been approved for marketing [22,23].
Other than PEGylated liposomes, higher and more selective
anti-cancer activity can be achieved through ligand-mediated
targeting liposomes. In this novel drug delivery system, targeting
moieties are coupled to the surface of liposomes to promote
selective binding to tumor-specific antigens and facilitate the
delivery of drug-containing liposomes to the intended cellular sites.
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than immunoconjugates and the multivalent presentation of
ligands leading to increased binding avidity [24]. Researchers
have already produced liposomes conjugated with various peptide
ligands that specifically target certain tumor cells or tumor
vasculature [25–29].
Because of the favorable selectivity and specificity, ligand-
conjugated liposomal anticancer drugs are a promising approach
for new chemotherapy research. The use of peptides as ligands to
direct liposomes to tumors represents a potentially feasible method
for increasing the specificity and effectiveness of liposome-
containing drugs [26,30]. Phage display is a technique of selecting
targeting peptides, in which a peptide is expressed on the surface
of a bacteriophage as a fusion-protein with one of the virion’s own
coat proteins [31]. Phage-displayed peptide libraries allows
researchers to map protein-protein contacts such as B-cell epitopes
[32–35] and receptor-ligand interactions [36]. Such peptide
libraries can also be used to identify organ- and cell-type-specific
peptides [26,27,37–39].
In this study, we used a phage-displayed peptide library to
identify a novel peptide that bound specifically to NSCLC cell
lines and surgical specimens from lung cancer patients. Liposomal
doxorubicin and vinorelbine conjugated with this targeting peptide
demonstrated enhanced accumulation of the drugs in tumor
tissues and improved therapeutic index for human lung cancer
xenografts in SCID mice.
Results
Isolation of phages binding to NSCLC cells
We used a phage-displayed random peptide library to isolate
phages that were able to bind to NSCLC CL1-5 cells. After five
rounds of affinity selection (biopanning) with CL1-5, cells
increased the titer of phage by 40-fold (Fig. 1A). Enriched phages
from the third to the fifth biopanning rounds were randomly
selected. We then sequenced the phage clones with higher CL1-5-
binding activities. Using the Genetics Computer Group (GCG)
software analysis, we found that these selected phages (PC3-1,
PC4-1, PC4-5, PC5-2 and PC5-4) displayed the consensus motif,
tryptophan (W)-threonine (T)/tyrosine (Y)-tyrosine (Y) (Table 1).
Interestingly, the phage PC5-2 appeared in the third (PC3-1),
fourth (PC4-1) and fifth (PC5-2) biopanning rounds. During the
biopanning rounds, the frequency of PC5-2 increased from 20%
(1/5) in the third cycle to 90% (27/30) in the fifth cycle (Table 1).
We chose to focus on the novel peptide displayed by PC5-2,
TDSILRSYDWTY, for further study.
Figure 1. In vitro phage display screening for peptides that bind to NSCLC. (A) A phage-displayed random peptide library was used to select
phages that bind to the NSCLC cell line CL1-5. (B) Visualization of PC5-2 binding to CL1-5 and PC13 lung cancer cells (arrowheads) with
immunohistochemical staining. The control phage did not bind to CL1-5 cells. Scale bar: 10 mm. (C) The FITC-labeled peptide SP5-2 bound to five
NSCLC cell lines but not to NPC-TW01 cells as detected by immunofluorescent staining. Scale bar: 10 mm. (D) Representative photomicrographs of
tumor sections from surgical specimens of human lung cancer were detected using both PC5-2 (a, arrowhead) and biotinylated SP5-2 (c, arrowhead),
respectively. In comparison, the control phage or biotinylated control peptide could not bind to these surgical specimens (b and d). PC5-2 was
competitively inhibited by the synthetic peptide SP5-2 (e). Mutated peptide, MP5-2, lost this competition ability (f). Scale bar: 25 mm.
doi:10.1371/journal.pone.0004171.g001
Table 1. Alignment of the phage-displayed peptide
sequences selected by NSCLC cells.
Phage clone Phage-displayed peptide sequence
a
5-2 TDSILRSYDWTY 27/30
5-4 DMPKQLLAPWYY 3/30
4-1 TDSILRSYDWTY 20/24
4-5 DMPKQLLAPWYY 2/24
4-9 SYPLSFLGPLIS 1/24
3-1 TDSILRSYDWTY 1/5
3-2 TQQPLEGHQLPY 1/5
3-3 TGVSWSVAQPSF 1/5
3-4 SVSVGMKPSPRP 1/5
3-5 SQWNSPPSSAAF 1/5
aPhage-displayed consensus amino acid sequences are shown in boldface.
doi:10.1371/journal.pone.0004171.t001
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NSCLC cells
To investigate whether PC5-2 would bind to NSCLC cells, we
used immunohistochemistry to locate the phage particles in
different cell types. Our results showed that PC5-2 bound
specifically to NSCLC cell lines including CL1-5 and PC13
(Fig. 1B, arrowheads). The control helper phage did not bind to
CL1-5 cells. PC5-2 bound neither to other cancer cell lines,
including oral cancer (SAS) and nasopharyngeal carcinoma cells
(NPC-TW01), nor to normal epithelial cells (NNM) from nasal
mucosa (Fig. 1B).
The CL1-5-binding ability of PC5-2 was further confirmed by a
peptide competitive inhibition experiment using immunofluores-
cent staining. The results showed that the binding activity of the
PC5-2 phage to CL1-5 cells was inhibited by the synthetic peptide
SP5-2inadose-dependent manner.Ata concentrationof27 mg/ml,
SP5-2 completely inhibited the binding activity of PC5-2 (Fig. S1).
The control phage did not bind to CL1-5 cells, and PC5-2 did not
bind to NPC-TW01 in this assay (Fig. S1 and Text S2).
To further verify that the PC5-2 phage would bind to a target
molecule expressed on the surface of CL1-5 cells, we measured
PC5-2-bound cells using flow cytometry (Fig. S2 and Text S1, S2).
A control phage was used to estimate non-specific background
binding (Fig. S2b). The results showed that 42.6% of CL1-5 cells
were bound by PC5-2 (Fig. S2c), and this binding was completely
inhibited by 27 mg/ml of SP5-2 peptide (Fig. S2d). PC5-2 did not
bind to SAS or NNM (Fig. S2 e and f).
Binding of synthetic peptide SP5-2 with lung cancer cells
and human lung cancer surgical specimens
To determine whether the peptide sequences displayed on PC5-
2 would actually interact with NSCLC cells, we used fluorescein
isothiocyanate (FITC)-labeled SP5-2 peptide (FITC-SP5-2) in
place of the PC5-2 phage for a peptide-binding assay through
immunofluorescent staining. FITC-SP5-2 specifically bound to all
of the NSCLC cell lines we tested, including CL1-5, H460, A549,
PC13 and H23, but did not bind to NNM. The same
concentration of FITC-labeled control peptide (FITC-Con-P)
revealed no such binding activity (Fig. 1C). We also evaluated the
magnitude and specificity of SP5-2 binding using flow cytometry.
The proportions of CL1-5, H460, A549, PC13 and H23 cells
bound by SP5-2 were 43.0%, 45.8%, 44.3%, 20.1% and 44.0%,
respectively (Fig. S3 and Text S2).
To determine whether this targeting ligand had an affinity for
human lung cancer surgical specimens, we tested the reactivity of
PC5-2 and SP5-2 with pulmonary adenocarcinoma cells using
immunohistochemistry. Both PC5-2 and biotin-labeled SP5-2 (B-
SP5-2) recognized the tumor cells of NSCLC surgical specimens
(Fig. 1D a and c, arrowheads), and the control phage and biotin-
labeled control peptide (B-Con-P) did not (Fig. 1D b and d). SP5-2
(TDSILRSYDWTY) competed with PC5-2 for binding to surgical
specimens of pulmonary adenocarcinoma (Fig. 1De), but the same
concentration of a mutated peptide, MP5-2 (TDSILRSYDGGG)
did not (Fig. 1Df). Seventy-five percent (27/36) of the pulmonary
adenocarcinoma specimens from 36 patients expressed a target
molecule that was recognized by this peptide (Table S1). These data
indicated that SP5-2 could recognize unidentified molecules
expressed on NSCLC cell lines and actual cancer cells from the
surgical specimens of lung cancer.
Mice models for the study of PC5-2-targeting ability
To investigate the targeting ability of the PC5-2 phage in vivo,w e
injected phages into the tail vein of mice bearing CL1-5-derived
tumors and then recovered them after perfusion. We determined
the titers of the phage in tumor masses and normal control organs
(brain, heart and lungs) [26,30]. PC5-2 showed specific homing to
tumor masses with concentrations 15-fold higher than its concen-
trationinthecontrolorgans(Fig.2A).Controlhelperphagesdidnot
show any specific targeting to tumor tissues (Fig. 2A).
The tumor-homing ability of PC5-2 was further confirmed by a
peptide competitive inhibition experiment, in which synthetic
peptide SP5-2, injected together with PC5-2, markedly inhibited
the recovery of the phage from tumor masses (Fig. 2B). One
hundred micrograms of SP5-2 inhibited 92% of PC5-2 binding to
tumor masses, but the same concentration of a control peptide had
no such inhibitory effect (Fig. 2B).
From in vitro phage display screening, we identified two clones
(PC5-2 and PC5-4) with a consensus motif of W-T/Y-Y (Table 1).
Like PC5-2, the tumor-homing ability of PC5-4 was also
competitively inhibited by SP5-2 (Fig. S4 and Text S2), suggesting
that these two phages may bind through this motif to the same
target molecule on the plasma membrane of lung cancer cells. We
proposed that these three amino acid residues might play a crucial
role in homing to tumor tissues. To test this hypothesis, we
changed these three amino acid residues in SP5-2 (TDSILR-
SYDWTY) to GGG in a mutant peptide, MP5-2 (TDSILR-
SYDGGG). Although the tumor-homing ability of PC5-2 had
been markedly inhibited by the peptide SP5-2, this competitive
inhibition was lost in MP5-2, which contains the GGG residue
instead of the WTY residues in SP5-2 (Fig. 2B). These data
indicate that the WTY residues were important for the binding
ability of SP5-2 to NSCLC cells.
The tissue distribution of PC5-2 was also studied using
immunostaining. We injected SCID mice bearing NSCLC
xenografts with PC5-2 and then removed and fixed the tumor
and control organs for localization of the phage particles. PC5-2
was found to localize in tumor tissues (Fig. 2Cd). At a higher
magnification, the immunoreactivity of the phage was detected on
the plasma membrane with some diffusion in the surrounding
cytoplasm of tumor cells (Fig. 2Ce). There was no reaction product
detected on normal organs such as brain, heart and lung tissues
(Fig. 2C a–c), nor on tumor tissues treated by the control phage
(Fig. 2Ci). The specific targeting of PC5-2 to the NSCLC
xenograft was inhibited by the synthetic peptide SP5-2 in the in
vivo homing experiment (Fig. 2Cj).
Therapeutic efficacy of SP5-2-mediated targeting
liposomes
To determine whether the lung cancer-targeting peptide SP5-2
could be used to improve the chemotherapeutic efficacy of cancer
treatment, we coupled the peptide to liposomes containing anti-
cancer drugs. SCID mice bearing size-matched, CL1-5-derived
xenografts were treated with (1) SP5-2-conjugated liposomal
doxorubicin (SP5-2-LD), (2) mutant peptide-conjugated liposomal
doxorubicin (MP5-2-LD), (3) non-targeted liposomal doxorubicin
(LD), (4) free doxorubicin (FD), or (5) equivalent volumes of
phosphate-buffered saline (PBS). All the formulations were
injected intravenously (i.v.) at a total doxorubicin dosage of
8 mg/kg (1 mg/kg twice a week for a total of eight injections).
The tumors in mice that received SP5-2-LD (Fig. 3A group a)
were significantly smaller than those in the MP5-2-LD, LD, FD,
and PBS groups (P,0.01) (Fig. 3A group b–e). The tumor sizes in
the LD and MP5-2-LD groups were 2.1 and 2.6 times larger than
those in the SP5-2-LD group, respectively. The tumor sizes in the
FD and control PBS groups were 7.0 and 8.3 times larger than
that in the SP5-2-LD group, respectively (Fig. 3A). Interestingly,
the greater therapeutic efficacy of SP5-2-LD was lost when the
Peptide for Targeted Therapy
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LD. Free doxorubicin exhibited little therapeutic efficacy at this
concentration, as the tumor size in this group was only 16%
smaller than that in the PBS group (Fig. 3A).
To verify whether large xenografts would respond to SP5-2-LD
treatment, mice bearing large lung cancer xenografts (500 mm
3)
were assigned to three treatment groups. After a course of
doxorubicin treatment with a total dosage of 16 mg/kg (2 mg/kg
twice a week for eight injections), the tumor sizes in the control
PBS and LD groups gradually increased to 3.3 and 2.1 times the
tumor size in the SP5-2-LD group (P,0.01) (Fig. 3B). These
results revealed that SP5-2-LD also increased the therapeutic
efficacy of doxorubicin in SCID mice bearing large lung cancer
xenografts.
To further test whether SP5-2 would optimize the therapeutic
index in lung cancer treatment, SP5-2-LD was used to treat a
different type of lung cancer xenograft (H460-derived tumor).
SCID mice bearing size-matched, H460-derived xenografts were
treated with SP5-2-LD, LD, FD, or equivalent volumes of PBS,
through i.v. injection at a total doxorubicin dosage of 8 mg/kg
(1 mg/kg twice a week for eight injections). The final tumor size in
the SP5-2-LD group was significantly smaller than those in the
LD, FD and PBS groups (P,0.05). Mice in the LD, FD and PBS
groups had tumors with sizes 2.0-, 8.6- and 10.0-fold larger than
that in the SP5-52-LD group (Fig. 3C). Free doxorubicin at this
concentration reduced the tumor size by only 14% compared with
PBS groups. Not only was tumor growth markedly suppressed in
the SP5-2-LD group (Fig. 3C), the body weight of the mice in this
group increased by 10.3% (2.38 g) at the end of the treatment
period. In contrast the LD-treated mice had a smaller increase in
body weight of 2.4% (0.59 g) (Fig. 3D).
To further confirm SP5-2 could increase the therapeutic index
for lung cancer, we linked the SP5-2 peptide to another anti-
cancer drug, liposomal vinorelbine (SP5-2-LV) and tested its
efficacy against lung cancer xenografts. SCID mice bearing size-
matched CL1-5-derived xenografts were given i.v. injections of
SP5-2-LV, liposomal vinorelbine (LV), or equivalent volumes of
PBS at a total vinorelbine dose of 24 mg/kg (2 mg/kg twice a
week for twelve injections). The tumor-bearing mice treated with
SP5-2-LV (Fig. 3E, group a) had significantly smaller tumors than
the LV and PBS groups (P,0.01) (Fig. 3E, group b and c). The
tumor size in the LV group was 6.75-fold larger than the SP5-2-
LV group. The average tumor size in the control PBS group was
25-fold larger than the SP5-2-LV group (Fig. 3E). To assess side
effects of the treatments, the mice were weighed twice a week. The
body weight of mice increased by 5.7% (1.37 g) in the SP5-2-LV
group and by 2.4% (0.58 g) in the LV group at the end of the
treatment period (data not shown).
Finally, we compared the survival rates of tumor-bearing mice
after treatment with SP5-2-LV, LV, or PBS over 102 days. All five
animals in the PBS-treated group died (survival rate 0%). Three
mice died in the LV-treated group (survival rate 40%). In the
Figure 2. Verification of tumor-homing ability of PC5-2 in vivo. (A) SCID mice bearing human lung cancer xenografts received i.v. injections of
PC5-2, and phage was recovered after perfusion. Recovery of PC5-2 from the tumor was markedly higher than from brain, heart or lungs. (B)
Targeting activity of PC5-2 to tumor tissues was competitively inhibited by SP5-2 but not by control peptide or mutant peptide. (C)
Immunohistochemical localization of PC5-2 after i.v. injection into mice with CL1-5-derived xenografts. The phage was localized on tumor tissues (d
and e) and no localization was observed in normal organs such as the brain (a), heart (b), and lungs (c), or in the tissue sections treated with the
control phage (f–i). The interaction of PC5-2 with the tumor section was inhibited by synthetic peptide SP5-2 (j). Scale bar: 25 mm.
doi:10.1371/journal.pone.0004171.g002
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significantly higher than the other two groups (Fig. 3F). These
experiments demonstrate that SP5-2 increased the therapeutic
efficiency of liposome-encapsulated doxorubicin and vinorelbine
with less toxicity.
Tumor localization and biodistribution of SP5-2-
conjugated targeting liposomes
The biodistribution and tumor localization of SP5-2-LD, MP5-
2-LD, LD, and FD were estimated by measuring the intrinsic
auto-fluorescence signal of doxorubicin in mice with NSCLC
xenografts. Doxorubicin (Mr 543.54), a small-molecule chemo-
therapeutic agent as its Mr is ,1000, has a poor pharmacokinetic
profile, and its blood concentration drops to background level
within one hour after administration (Fig. S5A and Text S2). The
pharmacokinetic profile of various liposomal doxorubicin formu-
lations, including SP5-2-LD, MP5-2-LD, and LD, were markedly
greater than FD (Fig. S5A). The area under the concentration-
time curve (AUC0–48 hours) of doxorubicin in tumor tissues was
10.4 mg?hr/g, 31.5 mg?hr/g, 29.0 mg?hr/g, and 59.9 mg?hr/g in
the FD, LD, MP5-2-LD, and SP5-2-LD groups, respectively
(Table S2). The mean intra-tumor doxorubicin concentration in
the SP5-2-LD-treated group was 5.7-, 1.9- and 2.1-fold higher
than the intra-tumor doxorubicin concentration in the FD, LD,
and MP5-2-LD groups (Fig. 4A and Table S2).
To assess the bioavailability of the liposomal drugs, we used
nuclear doxorubicin accumulation as an indicator of drug
cytotoxicity [40]. The AUC0–48 hours of bioavailable doxorubicin
(i.e., bound to nuclei) for FD, LD, MP5-2-LD, and SP5-2-LD
was 3.7 mg?hr/g, 6.7 mg?hr/g, 7.5 mg?hr/g, and 17.7 mg?hr/g,
respectively (Table S2). The intra-tumor nuclear doxorubicin
concentration in the SP5-2-LD group was 4.8-, 2.6- and 2.4-fold
higher than the nuclear doxorubicin concentration in the FD, LD,
and MP5-2-LD groups (Fig. 4B and Table S2). Doxorubicin
concentration inside tumor tissues and nucleus was not signifi-
cantly different between the LD and MP5-2-LD groups (Fig. 4 and
Table S2).
Enhanced tumor drug delivery and therapeutic efficacy
of SP5-2-conjugated liposomes
To compare the drug delivery profile of the four doxorubicin
formulations, we tried to detect the drug in tumor tissues using the
fluorescence microscope. Images from all tumors showed that
doxorubicin was visualized in the tumor nuclei one hour after SP5-
2-LD was administered, but not after other formulations were
injected (Fig. 5A). Over time, areas of tumor sections with
detectable doxorubicin increased. The areas with detectable
doxorubicin were significantly larger in SP5-2-LD-treated tumors
than that in FD, LD, and MP5-2-LD-treated tumors at each time
point (Fig. 5A). The MP5-2-LD formulation had the same
distribution pattern as LD, but the regions of FD-treated tumors
showed no detectable doxorubicin (Fig. 5A).
When the tumor tissues in each treatment group (Fig. 3C) were
examined by H&E staining, markedly disseminated necrotic/
apoptotic areas were present throughout the sections of SP5-2-LD-
treated xenografts (Fig. 5B). In addition, terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL) was used
to identify apoptotic cells and tomato lectin was applied to detect
tumor blood vessels. The tumors had larger apoptotic areas and a
Figure 3. Treatment of SCID mice bearing human lung cancer xenografts with SP5-2-LD or SP5-2-LV. (A) Median tumor volume over
time in mice treated with PBS, FD, LD, MP5-2-LD, or SP5-2-LD. Tumor growth was markedly suppressed in the SP5-2-LD treated group. SP5-2-LD has
higher therapeutic efficacy than LD and MP5-2-LD (n=6 in each group; **P,0.01). (B) Mice bearing size-matched CL1-5-derived lung cancer with
tumor size of approximately 500 mm
3 were treated with SP5-2-LD, LD, or PBS (n=6 in each group, **P,0.01). (C) Mice bearing H460-derived lung
cancer were treated with SP5-2-LD, LD, FD, or PBS (n=6 in each group, *P,0.05). (D) The effects of different treatments on change in body weight
over the treatment period (n=6 in each group). (E) Mice bearing CL1-5-derived lung cancer were treated with SP5-2-LV, LV, or PBS (n=6 in each
group; **P,0.01). (F) A Kaplan-Meier survival curve showed longer lifespan of mice treated with SP5-2-LV than those treated with LV and PBS (n=5 in
each group).
doi:10.1371/journal.pone.0004171.g003
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group than in the LD- and PBS-treated groups (Figs. 5B and S6).
The greater accumulation of anti-cancer drugs in tumor tissues
and more bioavailable doxorubicin in cancer cell nuclei from the
ligand-conjugated liposomes further demonstrated that the SP5-2
peptide recognized the target molecule on the surface of lung
cancer cells and thus increased direct drug delivery to the tumor.
Discussion
The therapeutic efficacy of anticancer drugs can be achieved by
enhancing the drug formulation with molecules that preferentially
bind to tumor tissues [22,26,37,41]. Phage display biopanning on
intact cell allows for the isolation of highly specific peptides that
target tumor-associated antigens. Anti-cancer regimens armed
with these peptides can be used as ‘‘cruise missiles’’ that are
precisely guided to the cancer cells and deliver high enough doses
to kill these cells with minimal damage to normal tissues.
In this study, we identified a NSCLC-targeting peptide and
demonstrated its improved therapeutic efficiency in animal
models. Specifically, we found a phage clone PC5-2 that made
up 90% of the selected phages binding to CL1-5 cells after five
rounds of biopanning (Table 1). Immunohistochemistry and flow
cytometry assays confirmed that PC5-2 bound to NSCLC cell
surface. The same binding results were observed in the cognate
synthetic peptide SP5-2, which replaced PC5-2 (Fig. 1 and Figs.
S1, S2, S3). These experiments supported that this targeting
peptide can specifically bind to the cell surface of NSCLC cell
lines. In vivo experiments also consolidated the homing ability of
the peptide. The expression of the SP5-2 peptide (TDSILR-
SYDWTY) guides the phage to accumulate in NSCLC xenografts
but not in normal organs (Fig. 2). The binding activity of PC5-2 to
tumor tissues was inhibited by the synthetic peptide SP5-2
(Fig. 2B), indicating that PC5-2 interacted with NSCLC cells by
its displayed peptide and not by another part of the phage particle.
That the mutated synthetic peptide, MP5-2, did not inhibit the
PC5-2 binding demonstrated the importance of the WTY motif in
the binding activity (Fig. 2B). Moreover, this phenomenon was
observed in immunohistochemical staining of surgical specimens
from human lung cancer (Fig. 1D e and f), in animal models for
ligand-targeted chemotherapy (Fig. 3A) and in tumor localization
of doxorubicin delivered by SP5-2-conjugated targeting liposomes
(Figs. 4 and 5A).
Immunohistochemistry assessments on pulmonary adenocarci-
noma surgical specimens demonstrated that SP5-2 has a clinical
potential as imaging probes to identify NSCLC or drug delivery
agents for the treatment of NSCLC. Both PC5-2 and biotin-
labeled SP5-2 detected pulmonary adenocarcinoma surgical
specimens in our experiments (Fig. 1D). Seventy-five percent
(27/36) of pulmonary adenocarcinoma specimens from 36 patients
expressed a target molecule that was recognized by the peptide
(Table S1). SP5-2, but not MP5-2, competed with PC5-2 for
binding to pulmonary adenocarcinoma surgical specimens
(Fig. 1D), which further confirmed the specificity of this targeting
ligand.
In previous studies, doxorubicin has largely been used in cancer
treatment because of its broad spectrum of antitumor activity.
However, the efficacy of doxorubicin in the treatment of NSCLC
remains unsatisfactory with a response rate of 15% [42]. This is in
part a result of suboptimal doses within the tumor due to
indiscriminate drug distribution throughout the body and severe
toxicity to normal tissues and organs. Liposomal encapsulation
with a targeting ligand may be an effective strategy to deliver the
drug directly to tumor cells. Our data revealed that this peptide
markedly increased the therapeutic efficacy of liposomal chemo-
therapies and resulted in higher survival rates in mice with human
lung cancer xenografts, and produced limited side effects on the
animals (Fig. 3). This peptide increased the therapeutic index of
not only doxorubicin but also of vinorelbine, a vinca alkaloid used
to treat advanced NSCLC [3]. Furthermore, we observed
decreased vessel density and substantially increased cell apoptosis
in tumor tissues after the targeting liposome treatment (Figs. 5B
and S6). This ligand-mediated liposomal formulation is potentially
superior to conventional anti-cancer therapy for NSCLC.
Our in vivo pharmacokinetic studies in mice showed that
liposomal doxorubicin dramatically changed the transportation
and distribution of doxorubicin in the heart, lungs, kidneys, and
liver in mice (Figs. 4 and S5). These results echo other similar
investigations [43,44]. With prolonged presence of liposomes in
circulation, more doxorubicin was taken up by tumor cells than
Figure 4. Tumor localization of different formulations of
liposomal and free doxorubicin in a NSCLC xenograft mouse
model. At selected time points (1, 4, 24 and 48 hours) after injection,
doxorubicin concentration in tumor tissues (A) and nuclei of cancer cells
(B) was measured. Doxorubicin concentration inside tumor tissues and
nuclei in the SP5-2-LD group was higher than in the FD, LD, and MP5-2-
LD groups (n=3 at each time point, *P,0.05, **P,0.01).
doi:10.1371/journal.pone.0004171.g004
Peptide for Targeted Therapy
PLoS ONE | www.plosone.org 6 January 2009 | Volume 4 | Issue 1 | e4171conventional doxorubicin administration (Fig. 4); this finding was
further confirmed in fluorescence signaling of doxorubicin in
tumor tissues (Fig. 5A). This passive targeting phenomenon of
non-ligand conjugated liposomes is called the ‘‘enhanced perme-
ability and retention effect’’ [45,46]. In our study, the doxorubicin
concentration in the LD-treated group was three times that of the
Figure 5. SP5-2 enhanced drug delivery to tumor tissues and increased therapeutic efficacy. (A) Representative two-color images
showing the distribution of doxorubicin (red) in relation to nuclei (blue) in tissue sections. Accumulation of doxorubicin in tumor tissues was shown
at 1, 4 and 24 hours post-injection. Bar, 50 mm. (B) Histopathology and fluorescent staining of tumor tissues in each treatment group examined after
staining with H&E, TUNEL (green), lectin (red), and DAPI (blue). Bar, 50 mm. Enhancement of drug accumulation in tumor tissues correlated with the
increased therapeutic efficacy.
doi:10.1371/journal.pone.0004171.g005
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had even higher doxorubicin concentration that was 1.9- and 2.1-
fold higher than those in the LD and MP5-2-LD groups (Table
S2). The bioavailable drug in the nuclei of cancer cells in the SP5-
2-LD was also 2.6- and 2.4-fold higher than those in the LD and
MP5-2-LD groups (Table S2). These results indicated that this
peptide directly delivered the chemotherapeutic drug to intended
targets. Enhancement of drug accumulation in tumor tissues
correlated with the increased therapeutic efficacy (Figs. 3, 4 and 5).
The peptide-functionalized liposomes were found to have
important clinical potential in a targeted drug delivery system.
In order to for them to be used clinically, however, a final targeting
liposome construct will need to be selected after each component,
i.e. peptide ligands, conjugation methodologies, and liposomal
drugs, have been optimized.
In conclusion, using phage display peptide libraries to screen for
peptides that bind to NSCLC cells, we identified several novel
peptidesincludingSP5-2thatspecificallyboundtothecellsurfaceof
NSCLC cells both in vitro and in vivo. Linking SP5-2 to liposomes
containing doxorubicin and vinorelbine increased the therapeutic
efficacy and survival rates in mice with human NSCLC xenografts
because of enhanced tumor apoptosis and decreased tumor
angiogenesis. Quantitation and visualization of doxorubicin levels
also showed increased drug concentration in tumor tissues in this
formulation, highlighting the enhancement in both the delivery and
penetration of doxorubicin into the tumor. Our results indicate that
theSP5-2tumortargetingpeptidemaybeusedasimaging probesof
NSCLC and targeting ligands for liposomal delivery systems to
increase the efficacy of chemotherapy for NSCLC.
Materials and Methods
Cell lines and cultures
Lung cancer cell lines (A549, CL1-5, H23, H460, and PC13), a
nasopharyngeal carcinoma cell line (NPC-TW01), an oral cancer
cell line (SAS), and human normal nasal mucosal epithelial (NNM)
cells were used in this study. The NNM cells were a primary
culture derived from a nasal polyp [27]. The A549, H23, and
H460 lines were obtained from the American Type Culture
Collection. The CL1-5 line was established by Chu et al. [47]. The
A549, CL1-5, H23 and H460 cells were grown in RPMI 1640
(Gibco, CA, USA) containing 10% fetal bovine serum (FBS,
Gibco, CA, USA) at 37uC in a 5% CO2 incubator. The NPC-
TW01, PC13, SAS, and NNM cells were grown in DMEM
(Gibco, CA, USA) containing 10% FBS at 37uC in a 10% CO2
incubator.
Phage display biopanning procedures
CL1-5 cells were first incubated with UV-treated inactive
control helper phage (insertless phage). The phage-displayed
peptide library (New England BioLabs, MA, USA), which initially
contained 5610
10 plaque-forming units (pfu), was then added. The
bound phages were eluted with a lysis buffer (150 mM NaCl,
50 mM Tris-HCl, 1 mM EDTA, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, pH 7.4) on ice. This eluted phage pool
was amplified and titered in an Escherichia coli ER2738 culture
(New England BioLabs, MA, USA). Recovered phages were used
as input for the next round of panning as described previously
[26,27].
Identification of phage clones using cellular enzyme-
linked immunosorbent assay (ELISA)
Ninty-six-well ELISA plates (Falcon, CA, USA) were seeded
with either cancer or control cells. Individual phage particles were
added to the cell-coated plates and incubated, followed by
incubation with horseradish peroxidase (HRP)-conjugated mouse
anti-M13 monoclonal antibody (mAb) (Pharmacia, Uppsala,
Sweden) and subsequently with the peroxidase substrate o-
phenylenediamine dihydrochloride (Sigma, MO, USA). The
reaction was stopped and absorbance was measured at 490 nm
using an ELISA reader. The selected phage clones were further
analyzed using DNA sequencing. The sequencing was performed
with the primer 59-CCCTCATAGTTAGCGTAACG-39 corre-
sponding to the pIII gene sequence. The phage-displayed peptide
sequences were translated and aligned using GCG program.
Peptide synthesis and labeling
The synthetic targeting peptide SP5-2 (TDSILRSYDWTY),
mutant peptide MP5-2 (TDSILRSYDGGG), and control peptide
(RLLDTNRPLLPY) [27] were synthesized (Invitrogene, Inc., CA,
USA) and purified using reverse-phase high-performance liquid
chromatography to .95% purity. Conjugation of these peptides
with FITC or biotin was performed through the addition of FITC
or biotin to the peptide amino terminus by the same company.
Identification of phages and synthetic peptides binding
to cancer cells
Cells were plated and grown to about 80% confluence on cover
slips. The cover slips were treated with 3% hydrogen peroxide plus
0.1% NaN3 to block endogenous peroxidase activity, and then
incubated with phages. After the cover slips had been washed and
fixed with 3% paraformaldehyde, they were incubated with HRP-
labeled mouse anti-M13 mAb and treated with peroxidase
substrate. For the peptide binding assays, 30 mg/ml FITC-labeled
SP5-2 or control peptide was added on each cover slip and
incubated. They were counterstained with Hoechst 33258
(Molecular Probes, OR, USA) and mounted with a mounting
solution (Vector, CA, USA). The cells were then examined under
a Leica universal microscope. The images were merged using the
SimplePCI software (C-IMAGING, PA, USA).
Binding of phages and synthetic peptides to surgical
specimens of lung cancer
For localization of peptide binding on lung cancer tissues, frozen
sections of NSCLC tissues were prepared and incubated with
phage clones or biotin-labeled peptides. For the peptide compet-
itive inhibition assay, phages were mixed with the synthetic
targeting or mutant peptide. The slides were subjected to routine
immunohistochemical staining [26,30]. All surgical specimens
were obtained from the tissue bank of National Taiwan University
Hospital (NTUH) with approval from the Institutional Review
Board in NTUH (IRB9461702021).
In vivo homing experiments and tissue distribution of
phages
SCID mice were injected subcutaneously (s.c.) in the dorsolat-
eral flank with 1610
7 human NSCLC cells. The mice bearing
size-matched lung cancer xenografts (approximately 500 mm
3)
were injected i.v. with 10
9 pfu of the targeting or control phage.
After perfusion, xenograft tumors and mouse organs were
removed and homogenized. The phages bound to each tissue
sample were recovered through the addition of ER2738 bacteria
and titered on IPTG/X-Gal agar plates. In the peptide
competitive inhibition experiments, the phages were injected
along with 100 mg synthetic targeting peptide, control peptide or
mutant peptide. The organs and tumor masses were fixed in
Bouin’s solution (Sigma, MO, USA). After fixation, the samples
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deparaffinized, rehydrated, and subjected to immunostaining
using the mouse M13 mAb as described above.
Preparation of synthetic peptide-conjugated liposomes
containing doxorubicin or vinorelbine
Peptide-conjugated liposomes containing doxorubicin or vinor-
elbine were prepared as described in other studies [26,27]. Briefly,
the peptide was coupled to NHS-PEG-DSPE [N-hydroxysuccini-
mido-carboxyl-polyethylene glycol (MW, 3400)-derived distear-
oylphosphatidyl ethanolamine] (NOF Corporation, Japan) in a
1:1.5 molar ratio. The reaction was completed and confirmed by
quantitation of the remaining amino groups using TNBS
(Trinitrobenzenesulfonate) reagent (Sigma, MO, USA). Doxoru-
bicin and vinorelbine were encapsulated in liposomes through a
remote loading method at a concentration of 1 mg of drug per
10 mmol phospholipids. Peptidyl-PEG-DSPE was transferred to
pre-formed liposomes after co-incubation at a transition temper-
ature of the lipid bilayer. There were 500 peptide molecules per
liposome as described previously [48].
Pharmacokinetic and biodistribution studies
SCID mice bearing NSCLC xenografts (,500 mm
3), were
injected in the tail vein with various formulations of liposomal
doxorubicin (SP5-2-LD, MP5-2-LD, and LD) and free doxorubi-
cin at a dose of 2 mg/kg. At selected time points, three mice in
each group were anaesthetized and sacrificed. Blood samples were
collected through submaxillary punctures, and plasma samples
were prepared. After perfusion, xenograft tumors and mouse
organs were removed and homogenized. Procedures for isolating
tumor cell nuclei and extracting nuclear doxorubicin were carried
out according to previous reports [40,49]. Total doxorubicin
concentration was measured using a method described by Mayer
et al. [49]. Total doxorubicin was quantified using spectrofluo-
rometry at lex 485/20 nm and lem 645/40 nm (Synergy HT
Multi-Detection Microplate Reader, BioTek Instruments, Wi-
nooski, VT 05404 USA).
To correct for background fluorescence, a standard curve was
obtained by spiking tissue extracts derived from mice that did not
receive doxorubicin. Tissue concentrations of doxorubicin were
expressed as microequivalents per milliliter of plasma or per gram
of tissue. A standard doxorubicin curve was prepared in control
homogenates following the same extraction procedure as above.
Drug levels were estimated on the basis of doxorubicin fluorescent
equivalents.
To determine the presence of the drug localized in tumor
tissues, doxorubicin autofluorescence was detected using a Zeiss
Axiovert 200 M inverted microscope with a 100 W HBO mercury
light source equipped with a 546/12 nm excitation and a 590 nm
emission filter set. Tissue sections were imaged with a FLUAR
106/0.50 NA lens and captured with a Roper Scientific CoolSnap
HQ CCD camera. All images were captured in 8-bit signal depth
and subsequently pseudo-colored.
Animal model for the study of ligand-targeted therapy
Mice 4–6 weeks of age were injected s.c. in the dorsolateral
flank with human NSCLC cells. Mice with size-matched tumors
(approximately 50–100 mm
3) were then randomly assigned to
different treatment groups and injected with SP5-2-LD or SP5-2-
LV, or LD or LV through the tail vein. The dosage of SP-5-2-LD
was 1 mg/kg injected twice a week for four weeks, and that of
SP5-2-LV was 2 mg/kg injected twice a week for six weeks. Mice
bearing large tumors (approximately 500 mm
3) were treated with
SP5-2-LD for eight times (2 mg/kg, twice a week for four weeks).
Mouse body weights and tumor sizes were measured twice a week.
Tumor volumes were calculated using the equation:
length6(width)
260.52. Animal care was carried out in accordance
with guidelines of Academia Sinica, Taiwan.
Terminal deoxynucleotidyl transferase–mediated dUTP
nick end labeling (TUNEL) staining
The frozen tumor tissue sections were incubated with terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling
reaction mixture (Roche Diagnostics) at 37uC for an hour. The
slides were counterstained with mounting medium with DAPI
(Vector Laboratories). The slides were then visualized under a
fluorescent microscope.
Vessel staining
Tissues were removed from treated mice, fixed with 4%
paraformaldehyde and embedded with paraffin. Blood vessels
were detected by staining of Lycopersicon esculentum (tomato) lectin
conjugated to biotin (Vector, CA, USA). The biotinylated lectin
was visualized with streptavidin-conjugated rhodamine (Pierce, IL,
USA).
Statistical analyses
We analyzed the data of phage titer, tumor volume, body
weight, and doxorubicin concentration using two-sided unpaired
Student’s t-test. We considered a P value below 0.05 as significant
for all analyses. All values are represented as mean6standard
deviation.
Supporting Information
Text S1 Supporting Information and figure legends
Found at: doi:10.1371/journal.pone.0004171.s001 (0.02 MB
DOC)
Text S2 Supplementary figure legend
Found at: doi:10.1371/journal.pone.0004171.s002 (0.03 MB
DOC)
Figure S1 Identification of PC5-2 binding to NSCLC cells.
Representative microscopy images of CL1-5 cells stained with
propidium iodide (a–f, red), anti-M13 monoclonal antibody (g–l,
green), and merge (m–r). The binding of PC5-2 to CL1-5 cells (a,
g, m) was inhibited by 3 mg/ml (b, h, n), 9 mg/ml (c, i, o), and
27 mg/ml (d, j, p) of SP5-2 in a dose-dependent manner. The
control phage and PC5-2 did not bind to CL1-5 cells (e, k, q) and
NPC-TW01 cells, respectively. Scale bar: 10 mm.
Found at: doi:10.1371/journal.pone.0004171.s003 (3.54 MB TIF)
Figure S2 The binding activity of PC5-2 to NSCLC cells was
analyzed by flow cytometry. The samples included cells only (a,
green), control phage (b, red), and PC5-2 (blue). The percentages
indicate the fraction of cells gated for positive binding (c). The
binding of PC5-2 to CL1-5 cells was completely inhibited by
27 mg/ml of SP5-2 (d). PC5-2 did not bind to SAS and NNM cells
(e, f).
Found at: doi:10.1371/journal.pone.0004171.s004 (2.42 MB TIF)
Figure S3 FITC-labeled SP5-2 binding to NSCLC cells was
analyzed by flow cytometry. The red line superimposed on all
panels represents the control phage. CL1-5, H460, A549, PC13,
and H23 panels showed positive binding, and the percentages
were 43, 45.8, 44.3, 20.1, and 44, respectively. There was only
background level in NPC-TW01 cells.
Found at: doi:10.1371/journal.pone.0004171.s005 (3.04 MB TIF)
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bearing NSCLC xenografts were injected i.v. with PC5-4, and
phage was recovered after perfusion. Recovery of PC5-4 from the
tumor was higher than from control organs. Targeting activity of
PC5-4 to tumor tissues was inhibited by SP5-2.
Found at: doi:10.1371/journal.pone.0004171.s006 (0.18 MB TIF)
Figure S5 Biodistribution of different formulations of liposomal
and free doxorubicin in a NSCLC xenograft mouse model. Mice
were i.v. injected with SP5-2-LD, MP5-2-LD, LD, and FD in a
single dose of 2 mg/kg. At selected time points (1, 4, 24 and
48 hours) after injection, doxorubicin concentration in blood, and
organs were measured (n=3 at each time point).
Found at: doi:10.1371/journal.pone.0004171.s007 (0.62 MB TIF)
Figure S6 Changes of lectin-reactive vessels in SP5-2-LD-
treated tumors. Positive lectin localization was quantified by pixel
area count (Metamorph software, MDS, Inc.) under low power
magnification.
Found at: doi:10.1371/journal.pone.0004171.s008 (0.20 MB TIF)
Table S1 Detection of human lung cancer surgical specimens by
PC5-2 using immunohistochemistry
Found at: doi:10.1371/journal.pone.0004171.s009 (0.06 MB
DOC)
TableS2 Tumor pharmacokinetics of free doxorubicin versus
liposomal doxorubicin formulations
Found at: doi:10.1371/journal.pone.0004171.s010 (0.03 MB
DOC)
Acknowledgments
The authors thank Dr. Yun-Long Tseng for the preparation of liposome
complexes, Mary Wyatt for reading the manuscript, and the Core Facility
of the Institute of Celluar and Organismic Biology, Academia Sinica, for
assistance in microscopy.
Author Contributions
Conceived and designed the experiments: HCW. Performed the
experiments: DKC CHW. Analyzed the data: DKC HCW. Contributed
reagents/materials/analysis tools: CTL HCW. Wrote the paper: DKC
HCW.
References
1. Boyle P, Gandini S, Gray N (2000) Epidemiology of lung cancer: a century of
great success and ignominious failure.; HH, ed. London: Martin Dunitz. pp
13–26.
2. Schiller JH (2001) Current standards of care in small-cell and non-small-cell lung
cancer. Oncology 61 Suppl 1: 3–13.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung
cancer. N Engl J Med 346: 92–98.
4. Jain RK (1996) 1995 Whitaker Lecture: delivery of molecules, particles, and cells
to solid tumors. Ann Biomed Eng 24: 457–473.
5. Jain RK (2001) Delivery of molecular and cellular medicine to solid tumors. Adv
Drug Deliv Rev 46: 149–168.
6. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, et al. (1995) Vascular
permeability in a human tumor xenograft: molecular size dependence and cutoff
size. Cancer Res 55: 3752–3756.
7. Boucher Y, Baxter LT, Jain RK (1990) Interstitial pressure gradients in tissue-
isolated and subcutaneous tumors: implications for therapy. Cancer Res 50:
4478–4484.
8. Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure
- an obstacle in cancer therapy. Nat Rev Cancer 4: 806–813.
9. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, et al. (1998) Elucidation
of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res
58: 1195–1201.
10. Park JW (2002) Liposome-based drug delivery in breast cancer treatment. Breast
Cancer Res 4: 95–99.
11. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, et al. (1999) Phase I
clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacryla-
mide copolymer doxorubicin]: first member of a new class of chemotherapeutic
agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II
Committee. Clin Cancer Res 5: 83–94.
12. Speth PA, van Hoesel QG, Haanen C (1988) Clinical pharmacokinetics of
doxorubicin. Clin Pharmacokinet 15: 15–31.
13. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999)
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.
Pharmacol Rev 51: 691–743.
14. Muggia F, Hamilton A (2001) Phase III data on Caelyx in ovarian cancer.
Eur J Cancer 37 Suppl 9: S15–18.
15. Colbern GT, Hiller AJ, Musterer RS, Pegg E, Henderson IC, et al. (1999)
Significant Increase in Antitumor Potency of Doxorubicin Hc1 by its
Encapsulation in Pegylated Liposomes. Journal of Liposome Research 9:
523–538.
16. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, et al.
(1991) Sterically stabilized liposomes: improvements in pharmacokinetics
and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 88: 11460–
11464.
17. Siegal T, Horowitz A, Gabizon A (1995) Doxorubicin encapsulated in sterically
stabilized liposomes for the treatment of a brain tumor model: biodistribution
and therapeutic efficacy. J Neurosurg 83: 1029–1037.
18. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, et al. (1994) Prolonged
circulation time and enhanced accumulation in malignant exudates of
doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res
54: 987–992.
19. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, et al. (2001)
Effective targeting of solid tumors in patients with locally advanced cancers by
radiolabeled pegylated liposomes. Clin Cancer Res 7: 243–254.
20. Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, et al. (2002) Dose
escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in
children with solid tumors: a pediatric oncology group study. Clin Cancer Res 8:
413–418.
21. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, et al. (2000) Pegylated
liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching
or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11: 1029–1033.
22. Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream.
Science 303: 1818–1822.
23. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev
Cancer 6: 688–701.
24. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev
Cancer 2: 750–763.
25. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, et al. (2005) Tumor-
specific targeting of an anticancer drug delivery system by LHRH peptide. Proc
Natl Acad Sci U S A 102: 12962–12967.
26. Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC (2007) Peptide-mediated
targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 67:
10958–10965.
27. Lee TY, Wu HC, Tseng YL, Lin CT (2004) A novel peptide specifically binding
to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res 64:
8002–8008.
28. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, et al. (2006) Targeting
liposomal chemotherapy via both tumor cell-specific and tumor vasculature-
specific ligands potentiates therapeutic efficacy. Cancer Res 66: 10073–10082.
29. Wu HC, Chang DK, Huang CT (2006) Targeted-therapy for cancer. J Cancer
Mol 2: 57–66.
30. Lo A, Lin CT, Wu HC (2008) Hepatocellular carcinoma cell-specific peptide
ligand for targeted drug delivery. Mol Cancer Ther 7: 579–589.
31. Smith GP (1985) Filamentous fusion phage: novel expression vectors that display
cloned antigens on the virion surface. Science 228: 1315–1317.
32. Chen YC, Huang HN, Lin CT, Chen YF, King CC, et al. (2007) Generation
and characterization of monoclonal antibodies against dengue virus type 1 for
epitope mapping and serological detection by epitope-based peptide antigens.
Clin Vaccine Immunol 14: 404–411.
33. D’Mello F, Partidos CD, Steward MW, Howard CR (1997) Definition of the
primary structure of hepatitis B virus (HBV) pre-S hepatocyte binding domain
using random peptide libraries. Virology 237: 319–326.
34. Liu IJ, Hsueh PR, Lin CT, Chiu CY, Kao CL, et al. (2004) Disease-specific B
Cell epitopes for serum antibodies from patients with severe acute respiratory
syndrome (SARS) and serologic detection of SARS antibodies by epitope-based
peptide antigens. J Infect Dis 190: 797–809.
35. Wu HC, Jung MY, Chiu CY, Chao TT, Lai SC, et al. (2003) Identification of a
dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of
DEN-2-immunized animal serum samples using an epitope-based peptide
antigen. J Gen Virol 84: 2771–2779.
36. Li B, Tom JY, Oare D, Yen R, Fairbrother WJ, et al. (1995) Minimization of a
polypeptide hormone. Science 270: 1657–1660.
37. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug
delivery to tumor vasculature in a mouse model. Science 279: 377–380.
Peptide for Targeted Therapy
PLoS ONE | www.plosone.org 10 January 2009 | Volume 4 | Issue 1 | e417138. Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display
peptide libraries. Nature 380: 364–366.
39. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, et al. (1998)
Molecular heterogeneity of the vascular endothelium revealed by in vivo phage
display. J Clin Invest 102: 430–437.
40. Laginha KM, Verwoert S, Charrois GJ, Allen TM (2005) Determination of
doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer
tumors. Clin Cancer Res 11: 6944–6949.
41. Hu W, Kavanagh JJ (2003) Anticancer therapy targeting the apoptotic pathway.
Lancet Oncol 4: 721–729.
42. Minna JD, Higgins GA, Glastein EJ (1982) Cancer: Principles of Practice of
Oncology Philadelphia; DeVita VT, Hellman S, Rosenberg SA, eds. Lippincott.
pp 396–474.
43. Gabizon A, Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal
doxorubicin. Rationale for use in solid tumours. Drugs 54 Suppl 4: 15–21.
44. Vaage J, Donovan D, Uster P, Working P (1997) Tumour uptake of doxorubicin
in polyethylene glycol-coated liposomes and therapeutic effect against a
xenografted human pancreatic carcinoma. Br J Cancer 75: 482–486.
45. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, et al. (1992)
Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice
bearing C-26 colon carcinoma. Cancer Res 52: 6774–6781.
46. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics
in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins
and the antitumor agent smancs. Cancer Res 46: 6387–6392.
47. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, et al. (1997) Selection of
invasive and metastatic subpopulations from a human lung adenocarcinoma cell
line. Am J Respir Cell Mol Biol 17: 353–360.
48. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, et al. (1997) Sterically
stabilized anti-HER2 immunoliposomes: design and targeting to human breast
cancer cells in vitro. Biochemistry 36: 66–75.
49. Mayer LD, Dougherty G, Harasym TO, Bally MB (1997) The role of tumor-
associated macrophages in the delivery of liposomal doxorubicin to solid murine
fibrosarcoma tumors. J Pharmacol Exp Ther 280: 1406–1414.
Peptide for Targeted Therapy
PLoS ONE | www.plosone.org 11 January 2009 | Volume 4 | Issue 1 | e4171